Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019.
Chen, Kuan-Hsuan a,b; Wang, Sheng-Fan a,b,c; Wang, Szu-Yu a; Yang, Yi-Ping d,e; Wang, Mong-Lien c,d; Chiou, Sih-Hwa d,e; Chang, Yuh-Lih a,b,e,*
[Review]
Journal of the Chinese Medical Association.
83(9):817-821, September 2020.
(Format: HTML, PDF)
As the coronavirus disease 2019 (COVID-19, also called severe acute respiratory syndrome coronavirus-2) outbreak accelerates, vigorous and diverse efforts were made in developing treatment strategies. In addition to direct acting agents, increasing evidence showed some potential adjuvant therapies with promising efficacy against COVID-19. These therapies include immunomodulators (i.e. intravenous immunoglobulin, thymosin [alpha]-1, interleukin [IL]-6, tocilizumab, cyclosporine, thalidomide, fingolimod), Chinese medicines (i.e. glycyrrhizin, baicalin, Xuebijing), anti-vascular endothelial growth factors (bevacizumab), estrogen modulating drugs, statins, and nutritional supplements (i.e. vitamins A, B, C, D, E and zinc). This article reviewed the pharmacological development of potential adjuvants for COVID-19 treatment.
(C) 2020 by Lippincott Williams & Wilkins, Inc.